Trade Vir Biotechnology VIR

Magbenta
 Bumili

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Mga Pangunahing Kaalaman sa Instrumento

Weekly Search
Weekly
Daily
Petsa Isarado Pagbabago Change (%) Buksan High Low

VirBiotechnology news

Mga pinakabagong balita

Ipakita nang marami
Noah Lee 2025 Sep 12, 10:20

US-Japan Joint Statement: Reaffirming Market-Driven Exchange Rates

Emma Rose 2025 Sep 12, 09:20

Goldman Sachs, UBS Raise Gold Price Forecasts for 2025

Noah Lee 2025 Sep 12, 09:20

Albania Appoints AI Minister to Combat Corruption in Public Procurement

Emma Rose 2025 Sep 11, 15:20

Dalio: Gold as a Hedge Against Mounting Debt Risks

Ava Grace 2025 Sep 11, 14:20

Switzerland Proposes US Gold Refinery to Reduce Tariffs

Noah Lee 2025 Sep 11, 14:20

NATO and EU on Edge After Russian Drone Enters Poland: A Critical Test

Liam James 2025 Sep 11, 10:20

Economists Anticipate BOJ Rate Hike in Q4 Amidst Global Uncertainties

Sophia Claire 2025 Sep 11, 10:20

Fed Rate Cut Debate Intensifies: Employment Data Revision Fuels Calls for Action

Info

Spread

0.05

Spread (%)

0.9615 %

Leverage

1:10

Interes sa Magdamagang Pagbili

-0.0597 %

Interes sa Magdamagang Pagtinda

-0.0292 %

Currency

USD

Trading Hours

Oras ng Pagsasara

Biyernes

13:31 - 19:59

Lunes

13:31-19:59

Martes

13:31-19:59

Miyerkules

13:31-19:59

Huwebes

13:31-19:59

Analys och statistik

Buksan

---

Nakaraang Pagsara

---

52 Linggo Mataas/Mababa

--- – ---

Market Cap

712639104

Natitirang Pagbabahagi

138916000

Petsa ng Mga Kita (Susunod)

0000-00-00

Pambayad si dividend

Araw ng Pag-alis ng Karapatan sa Dividend

Inaasahang Taunang Rate ng Dividend

0

Inaasahang Taunang Dividend Yield

0

EPS

-4.01

Alamin ang Higit Pa Tungkol sa Instrumentong ito

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Mga kaugnay na instrumento

Asset
Magbenta
Bumili
Change (%)

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon

Mag-trade Ngayon
view_all_instruments

latest_education_articles

Ipakita nang marami
Trustpilot